These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR. Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693 [TBL] [Abstract][Full Text] [Related]
46. [Novel pharmacologic therapies in acromegaly]. Góth M; Hubina E; Kovács L; Szabolcs I Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860 [TBL] [Abstract][Full Text] [Related]
47. A prospective multicenter octreotide dose response study in the treatment of acromegaly. Ezzat S; Redelmeier DA; Gnehm M; Harris AG J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225 [TBL] [Abstract][Full Text] [Related]
48. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434 [TBL] [Abstract][Full Text] [Related]
49. The pharmacological aspects of the treatment of acromegaly. Giustina A; Zaltieri G; Negrini F; Wehrenberg WB Pharmacol Res; 1996; 34(5-6):247-68. PubMed ID: 9076850 [No Abstract] [Full Text] [Related]
50. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly. Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976 [TBL] [Abstract][Full Text] [Related]
54. Emerging indications for octreotide therapy, Part 1. Mosdell KW; Visconti JA Am J Hosp Pharm; 1994 May; 51(9):1184-92. PubMed ID: 8042637 [TBL] [Abstract][Full Text] [Related]
55. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. Cozzi R; Montini M; Attanasio R; Albizzi M; Lasio G; Lodrini S; Doneda P; Cortesi L; Pagani G J Clin Endocrinol Metab; 2006 Apr; 91(4):1397-403. PubMed ID: 16449332 [TBL] [Abstract][Full Text] [Related]
58. Biliary colic on abrupt withdrawal of octreotide. James RA; Rhodes M; Rose P; Kendall-Taylor P Lancet; 1991 Dec; 338(8781):1527. PubMed ID: 1683947 [No Abstract] [Full Text] [Related]
59. Complications of long-acting somatostatin analogue therapy. Jackson JA Am J Med; 1989 Apr; 86(4):512-3. PubMed ID: 2929652 [No Abstract] [Full Text] [Related]
60. Sandostatin-induced thrombocytopenia. Hanna WT; Maull KI South Med J; 1990 Jan; 83(1):77. PubMed ID: 2300842 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]